Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Mesenchymal Stem Cells

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Virus antibody responses in patients with myelin oligodendrocyte glycoprotein antibody-associated disease and multiple sclerosis.

Multiple sclerosis and related disorders·2026

Same author

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

BMC medical research methodology·2022

Same author

Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.

Journal of neuroimmunology·2022

Same author

Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

Multiple sclerosis and related disorders·2020

Same author

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2019

Same author

The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis.

Multiple sclerosis and related disorders·2017

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Hematopoietic stem cell transplantation in multiple sclerosis.

C Rogojan¹, J L Frederiksen

¹Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark.

Acta Neurologica Scandinavica

|September 30, 2009

Summary

Hematopoietic stem cell transplantation (HSCT) offers hope for severe multiple sclerosis (MS) patients, with significant improvement seen in nearly 70% of cases. This treatment can reduce lesions and slow brain atrophy, potentially restoring self-tolerance.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Related Experiment Videos

Last Updated: Jun 20, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Area of Science:

Neuroimmunology
Hematology
Transplantation Medicine

Background:

Severe multiple sclerosis (MS) poses significant challenges for conventional therapies.
Hematopoietic stem cell transplantation (HSCT) has emerged as a potential treatment option for refractory MS.
Understanding the long-term efficacy and safety of HSCT in MS is crucial.

Purpose of the Study:

To comprehensively review the outcomes of hematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) patients.
To evaluate the effectiveness of HSCT in stabilizing or improving MS progression.
To analyze factors influencing HSCT outcomes, including patient selection and conditioning regimens.

Main Methods:

Systematic review of single-center and multicenter studies on HSCT for MS.
Monitoring of patient characteristics, transplantation procedures, toxicity, and clinical outcomes.
Comparison of results across different studies and patient cohorts.

Main Results:

Stabilization or improvement observed in nearly 70% of approximately 400 HSCT-treated MS patients for at least 3 years.
Significant reduction in gadolinium-enhancing lesions and a decline in brain atrophy progression post-HSCT.
Transplant-related mortality has decreased over time, with no reported deaths since 2001.

Conclusions:

Autologous HSCT can induce profound immunological changes, potentially restoring self-tolerance in MS patients.
Optimal candidates for HSCT include young patients with active disease, rapid progression, and low disability scores unresponsive to standard treatments.
Patient selection, timing of transplantation, and conditioning regimens are critical determinants of HSCT efficacy and safety in MS.